MedTech

Asia Pacific's share of global medtech demand is expected to reach $132 billion by 2030, growing at 6.9 percent annually and faster than the global market, according to a new report by Bain & Company.

ChemT Biotechnology, an AI-driven biotechnology company based on Singapore, has closed a $4 million seed round led by Wavemaker Ventures and co-investment partner SEEDS, an arm of SG Growth Capital, with support from Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.

Ovum, an Australian women's health company founded by Ariella Heffernan-Marks, has raised $4 million in seed funding to address the gender health gap, tripling its valuation just one year after securing $1.7 million in a pre-seed round.

Japan's Murata Electronics and Signapore-based Tribe, an open innovation platform, have launched KUMIHIMO Tech Camp Singapore 2026, an open innovation programme inviting MedTech startups across ASEAN and India to co-develop healthcare solutions addressing the region's most pressing medical challenges.

Brano Therapeutics, a spin-off from Singapore's Duke-NUS Medical School, has secured $6.8 million in seed funding to support the development of new treatments for heart failure, including heart failure with preserved ejection fraction (HFpEF), a condition with limited therapeutic options.

A growing population of more than 600 million with a combined GDP of more than $3 trillion and a rapid growth of the middle class are expected to fuel strong demand in healthcare coverage in Southeast Asia.

Led by CR-CP Life Science Fund, this new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.

Tokyo-based DCI Partners, a venture fund manager of Daiwa Securities Group, has announced the launch of Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II, a $135 million (JPY 14 billion) investment fund intended for drug discovery.

Next, the startup is expanding across Southeast Asia.